AstraZeneca Plc agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion in a deal that will see the British ...

(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

The FTSE 100 index is set for a flat start to the session as attention turns to an important week for monetary policy ...

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...

Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...